Drug Trial Radar · NCT05308472
Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Oct 31, 2022
Primary completion
Feb 20, 2024
Study completion Aug 23, 2024
Sponsor
- Lead sponsor
- Disc Medicine, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multi-center, double-blind, placebo-controlled, parallel group study of bitopertin to evaluate the safety, tolerability, efficacy, and PPIX concentration change in participants with EPP. Participants may roll over to an open label extension portion after completing the double-blind treatment period.
Conditions
- Erythropoietic Protoporphyria
Interventions
DISC-1459Drug
Oral dose level 1, once a day for 120 days
DISC-1459Drug
Oral dose level 2, once a day for 120 days
PlaceboDrug
Oral dose, once a day for 120 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Whole Blood Metal-free PPIX LevelsTime frame: 121 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Hospital
Birmingham, Alabama
University of California San Francisco
San Francisco, California
University of Miami Miller School of Medicine
Miami, Florida
Massachusetts General Hospital
Boston, Massachusetts
Mount Sinai Hospital
New York, New York
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina
Einstein Medical Center
Philadelphia, Pennsylvania
University of Texas
Galveston, Texas
Fred Hutchinson Cancer Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.